Why this research is relevant to clinicians today & researchers in the future WASHINGTON, D.C.—The ACR Convergence 2024 meeting in Washington, D.C., reflected the continued advancement of science and practical research in the field of rheumatoid arthritis. Highlights this year centered on new RA treatments and new uses of existing treatments; the use of artificial…
Our understanding of (axSpA) has really changed, especially with regard to male-female differences. In this report, we identify important research on axSpA presented at ACR Convergence 2024, summarize the abstracts and comment on why each is important, addressing the relevance for clinicians and the potential impact on future research.
At this ACR Convergence 2024 session, Sonye Danoff, MD, PhD, discussed many factors that need to be considered before referring patients with SARD-ILD for lung transplantation.
As rheumatology care evolves into a team-based approach, the workforce is expanding to incorporate advanced practice providers, physical therapists and social workers, all of whom can play vital roles in patient care.
Vitamin D has gotten a lot of press over the years. But is it actually worth the hype, especially when it comes to autoimmunity? Does it prevent the onset of autoimmune disease? Does it have a role in treatment? Experts in this ACR Convergence 2024 session helped decipher the role of vitamin D in bone health, immune regulation and infection reduction.
At this ACR Convergence 2024 session, the focus was on the identification & treatment of a newly identified syndrome of undifferentiated recurrent fever (SURF).
Experts shared insights into their work on building consensus for the use of musculoskeletal ultrasound for the diagnosis and management of RA and PsA.
The 2024 ACR Awards of Distinction honor members for their outstanding contributions to the field of rheumatology.
Two new treatment studies among patients with systemic lupus erythematosus and lupus nephritis had promising results.
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.